Product
GP+PD-1+Tight
1 clinical trial
1 indication
Indication
CholangiocarcinomaClinical trial
A Study to Evaluate GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Participants With Unresectable Advanced Biliary Tract Carcinoma (BTC)Status: Active (not recruiting), Estimated PCD: 2023-01-18